Product image of Imuldosa (Ustekinumab) supplied by GNH India

Imuldosa

Active Ingredient:
Ustekinumab
Origin:
EU

Imuldosa (Ustekinumab)

Ustekinumab, the active ingredient in Imuldosa, is a monoclonal antibody presented as a sterile solution for intravenous and subcutaneous use. It modulates immune activity and is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adult patients with moderate to severe disease.

GNH India supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution throughout.

Manufacturer / TM Owner

Accord Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imuldosa (ustekinumab) targets the interleukin‑12/23 pathway in immune‑mediated inflammatory diseases.

  • Plaque psoriasis: reduces skin lesions, scaling and erythema, leading to improved Psoriasis Area and Severity Index scores.
  • Psoriatic arthritis: improves joint pain, swelling and stiffness, and helps prevent radiographic progression.
  • Crohn's disease: induces clinical remission and maintains response in moderate to severe intestinal inflammation.
  • Ulcerative colitis: achieves clinical remission and promotes mucosal healing in adult patients with active disease.

How It Works

  • Ustekinumab is a human IgG1 kappa monoclonal antibody that binds with high affinity to the p40 subunit shared by interleukin‑12 and interleukin‑23. By preventing these cytokines from interacting with their cell‑surface receptors, the drug blocks downstream Th1 and Th17 inflammatory signaling pathways, leading to reduced production of pro‑inflammatory mediators in the immune system thereby helping to control chronic autoimmune activity.

Side Effects

Ustekinumab may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Injection site reactions: pain, redness, or swelling.
  • Upper respiratory infections: nasopharyngitis or mild sinusitis.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Infections: opportunistic infections such as tuberculosis or fungal infections.
  • Allergic reactions: anaphylaxis or severe hypersensitivity.
  • Malignancies: potential increased risk of certain cancers.

Precautions & Warnings

When prescribing ustekinumab, clinicians should consider several precautionary measures to ensure patient safety.

  • Infection screening: evaluate for active tuberculosis and chronic infections before initiation.
  • Vaccination status: administer required vaccines prior to therapy, avoiding live vaccines during treatment.
  • Monitoring: regularly assess for signs of infection, malignancy, and cardiovascular events.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
  • Concomitant immunosuppression: exercise caution when combined with other immunosuppressive agents.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ustekinumab can interact with other medicines, primarily affecting immune function or infection risk.

Major Interactions (Avoid)

  • Live vaccines: concurrent use may cause severe infection.
  • Antifungal agents: may increase risk of opportunistic infections when combined.

Moderate Interactions (Monitor Closely)

  • Other biologics: combined immunosuppression may heighten infection risk.
  • Systemic corticosteroids: may augment immunosuppressive effect.
  • Immunomodulators (e.g., methotrexate): monitor for additive toxicity.

Frequently Asked Questions

Imuldosa, containing ustekinumab, is approved for adult patients with moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. These are chronic immune‑mediated inflammatory disorders where targeting interleukin‑12/23 pathways can improve clinical outcomes.

Ustekinumab is a human IgG1 monoclonal antibody that binds the p40 subunit shared by interleukin‑12 and interleukin‑23. By blocking these cytokines from engaging their receptors, it suppresses Th1 and Th17 driven inflammation, reducing the release of downstream pro‑inflammatory mediators.

The dosing regimen for Imuldosa is individualized by the prescribing clinician based on factors such as the specific indication, patient body weight, disease severity, and prior treatment response. Exact dose amounts and intervals are established in the product’s prescribing information.

Safety data for ustekinumab in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To request Imuldosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Imuldosa (ustekinumab) targets the IL‑12/23 pathway, whereas alternatives such as secukinumab inhibit IL‑17, and TNF‑α inhibitors block tumor necrosis factor. Clinical choice depends on disease phenotype, prior therapy response, safety profile, and patient preference; ustekinumab offers a distinct mechanism that may be effective when TNF or IL‑17 blockers have failed.

Imuldosa should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Imuldosa is supplied as a sterile injectable solution. The initial dose is given intravenously in a clinical setting, followed by subcutaneous maintenance injections at intervals defined by the prescriber. Administration must be performed by qualified healthcare personnel.

Serious adverse events include opportunistic infections such as tuberculosis or fungal infections, severe hypersensitivity reactions including anaphylaxis, and a potential increased risk of certain malignancies. Patients should be monitored closely for signs of infection, allergic response, or unexpected cancer development.

Imuldosa is contraindicated in patients with known hypersensitivity to ustekinumab or any of its excipients. It should also be avoided in individuals with active, untreated tuberculosis or uncontrolled serious infections, and in those for whom live vaccines are required during therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ustekinumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT